JP Morgan Chase
ABUS icon

JP Morgan Chase’s Arbutus Biopharma ABUS Stock Holding History

JP Morgan Chase’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-129,000
Closed -$462K – 5738
2019
Q1 		$462K Buy
129,000
+54,000
+72% +$207K ﹤0.01% 4246
2018
Q4 		$287K Buy
75,000
+8,000
+12% +$39.4K ﹤0.01% 4417
2018
Q3 		$633K Buy
+67,000
New +$665K ﹤0.01% 4172

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

JP Morgan Chase's ABUS Position: Q1 2026 in Review

JP Morgan Chase reduced its Arbutus Biopharma (ABUS) stake by 11% in Q1 2026, selling an estimated $47.3K and leaving 87,049 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #5184.

JP Morgan Chase first reported a position in ABUS in Q2 2015 and has held it in 37 quarters since. The position peaked at $2.93M in Q4 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • JP Morgan Chase held 87,049 shares of Arbutus Biopharma worth $374K as of Q1 2026.
  • JP Morgan Chase sold 10,826 Arbutus Biopharma shares in Q1 2026, an estimated $47.3K.
  • Arbutus Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5184 holding.
  • JP Morgan Chase first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 37 quarters since.
  • JP Morgan Chase's Arbutus Biopharma position peaked at $2.93M in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.